Background: In July 2008, cetuximab treatment for unresectable advanced or recurrent colorectal cancer was approved in Japan, but there have been few reports on this therapy in Japan.
Purpose: We retrospectively analyzed the efficacy and safety of cetuximab(Cmab)+irinotecan(CPT-11)for unresectable advanced or recurrent colorectal cancer from October 2008 to April 2010 at 5 centers in the Kanagawa region.
Patients and methods: The number of patients enrolled was 38, all of whom were treated after second-line therapy.
Results: The RR was 24%. DCR was 68%. TTF was 105 days and OS was 242 days.
Conclusion: At 5 centers, Cmab+CPT-11 was an effective and safe treatment after second-line therapy.